



GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd/Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Mark Hackett**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 10<sup>th</sup> September 2021  
Ein Cyf / Our Ref: 21-H-023

01639 648363

FOIA.Requests@wales.nhs.uk

[Redacted]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 18<sup>th</sup> August 2021. Your request sought information relating to dermatology medication.

Please note we have provided this information for the period 01.03.21 to 30.06.21

**1. How many patients were treated in last 4 months by the Dermatology department with each of the following:**

- Abrocitinib - 0
- Acitretin - 73
- Alitretinoin - 16
- Azathioprine - 39
- Baricitinib - 0
- Ciclosporin - 23
- Dupilumab - 87
- Methotrexate - 154
- Mycophenolate mofetil - 17
- Pimecrolimus - 7
- Tacrolimus ointment - 11
- Tralokinumab - 0
- Upadacitinib - 0

**2. For all the patients treated by the Dermatology department in the last 4 months with the products listed in the previous question, can you please**



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

**tell us how many of these patients were paediatric (age 17 and under) versus adult?**

- Abrocitinib - 0
- Acitretin - <5
- Alitretinoin - 0
- Azathioprine - <5
- Baricitinib - 0
- Ciclosporin - 0
- Dupilumab - 7
- Methotrexate - <5
- Mycophenolate mofetil - 0
- Pimecrolimus - <5
- Tacrolimus ointment - <5
- Tralokinumab - 0
- Upadacitinib - 0


Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



On behalf of

Pam Wenger

**Director of Corporate Governance**

